


# Unlocking R&D productivity

Measuring the return from pharmaceutical innovation 2018


## 2018 results for large cap biopharma companies






The cost to bring an asset to market has **increased** to **record levels** in 2018

**\$2,168m**

**\$1,188m**



**Late-stage pipelines** are increasingly comprised of **oncology** assets




Forecast peak sales per asset have **more than halved** since 2010

## 2018 results for smaller, more specialised biopharma companies

More specialised biopharma companies are **outperforming** large cap biopharma, despite the higher development cost, due to **higher projected pipeline values**



## Unlocking R&D productivity by embracing the future of work



**Deloitte.**

Deloitte Centre for Health Solutions

This publication has been written in general terms and we recommend that you obtain professional advice before acting or refraining from action on any of the contents of this publication. Deloitte LLP accepts no liability for any loss occasioned to any person acting or refraining from action as a result of any material in this publication.

Deloitte LLP is a limited liability partnership registered in England and Wales with registered number OC303675 and its registered office at 1 New Street Square, London EC4A 3HQ, United Kingdom.

Deloitte LLP is the United Kingdom affiliate of Deloitte NWE LLP, a member firm of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"). DTTL and each of its member firms are legally separate and independent entities. DTTL and Deloitte NWE LLP do not provide services to clients. Please see www.deloitte.com/about to learn more about our global network of member firms.

© 2018 Deloitte LLP. All rights reserved.

Designed and produced by 368 at Deloitte. J17060